This protocol is for adults with type 2 diabetes who have obesity together with symptomatic heart failure with preserved ejection fraction (HFpEF). In this combination, the choice of glucose-lowering therapy is guided not by glycaemic targets alone — the cardiac and metabolic overlap defines which agents are appropriate.
The glucose-lowering plan in this setting involves an SGLT2 inhibitor and/or an agent from the GLP-1 receptor agonist class, selected specifically for demonstrated benefit in symptomatic HFpEF and obesity.
The complete protocol — including agent selection, clinical criteria, and the full structured regimen — is available via the link below.
DOI: 10.2337/dc26-S009
In adults with type 2 diabetes, obesity, and symptomatic heart failure with preserved ejection fraction (HFpEF), the glucose-lowering treatment plan should include a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA with demonstrated benefits for HF-related symptoms and reduction in HF events (irrespective of A1C).
In adults with type 2 diabetes, obesity, and symptomatic HFpEF, the glucose-lowering treatment plan should include a GLP-1 RA with demonstrated benefits for HF-related symptoms and/or reduction in HF events (irrespective of A1C).
View source ↗